Advertisement
Short Communication| Volume 209, ISSUE 4, P171-176, April 2016

Download started.

Ok

Clinical characteristics and genetic subtypes of Fanconi anemia in Saudi patients

      We reviewed our institutional experience from 2011 to 2015 on new cases of Fanconi anemia (FA). Ten unrelated cases were diagnosed during this period. Four patients with severe aplastic anemia (SAA) had c.2392C > T (p.Arg798*) BRIP1/FANCJ mutation. Another child with SAA had novel c.1475T > C (p.Leu492Pro) FANCC mutation. One individual with SAA and acute myeloid leukemia had c.637_643del (p.Tyr213Lysfs*6) FANCG mutation. Three patients presented with early onset of cancer, two had BRCA2 mutation c.7007G > A (p.Arg2336His) and one had a novel c.3425del (p.Leu1142Tyrfs*21) PALB2 mutation. Another infant with c.3425del PALB2 mutation had clonal aberration with partial trisomy of the long arm of chromosome 17. Mutations in FA downstream pathway genes are more frequent in our series than expected. Our preliminary observation will be confirmed in a large multi-institutional study.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kee Y.
        • D'Andrea A.D.
        Molecular pathogenesis and clinical management of Fanconi anemia.
        J Clin Invest. 2012; 122: 3799-3806
        • Wang A.T.
        • Smogorzewska A.
        SnapShot: Fanconi anemia and associated proteins.
        Cell. 2015; 160: 354-354.e1
        • Alter B.P.
        • Kupfer G.
        Fanconi anemia.
        in: Pagon R.A. Adam M.P. Ardinger H.H. Gene Reviews. University of Washington, Seattle, WA2013
        • Ayas M.
        • Siddiqui K.
        • Al-Jefri A.
        • et al.
        Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia.
        Biol Blood Marrow Transplant. 2014; 20: 1599-1603
        • Schwarz J.M.
        • Rodelsperger C.
        • Schuelke M.
        • et al.
        MutationTaster evaluates disease-causing potential of sequence alterations.
        Nat Methods. 2010; 7: 575-576
        • Levitus M.
        • Waisfisz Q.
        • Godthelp B.C.
        • et al.
        The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J.
        Nat Genet. 2005; 37: 934-935
        • Levitus M.
        • Rooimans M.A.
        • Steltenpool J.
        • et al.
        Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes.
        Blood. 2004; 103: 2498-2503
        • Tamary H.
        • Nishri D.
        • Yacobovich J.
        • et al.
        Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry.
        Haematologica. 2010; 95: 1300-1307
        • Litman R.
        • Peng M.
        • Jin Z.
        • et al.
        BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.
        Cancer Cell. 2005; 8: 255-265
        • Levran O.
        • Attwooll C.
        • Henry R.T.
        • et al.
        The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
        Nat Genet. 2005; 37: 931-933
        • Howlett N.G.
        • Taniguchi T.
        • Olson S.
        • et al.
        Biallelic inactivation of BRCA2 in Fanconi anemia.
        Science. 2002; 297: 606-609
        • Offit K.
        • Levran O.
        • Mullaney B.
        • et al.
        Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.
        J Natl Cancer Inst. 2003; 95: 1548-1551
        • Hirsch B.
        • Shimamura A.
        • Moreau L.
        • et al.
        Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood.
        Blood. 2004; 103: 2554-2559
        • Wagner J.E.
        • Tolar J.
        • Levran O.
        • et al.
        Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia.
        Blood. 2004; 103: 3226-3229
        • Reid S.
        • Schindler D.
        • Hanenberg H.
        • et al.
        Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
        Nat Genet. 2007; 39: 162-164
        • Tischkowitz M.
        • Xia B.
        PALB2/FANCN: recombining cancer and Fanconi anemia.
        Cancer Res. 2010; 70: 7353-7359
        • Xia B.
        • Sheng Q.
        • Nakanishi K.
        • et al.
        Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
        Mol Cell. 2006; 22: 719-729
        • Zhang F.
        • Ma J.
        • Wu J.
        • et al.
        PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
        Curr Biol. 2009; 19: 524-529
        • Rahman N.
        • Seal S.
        • Thompson D.
        • et al.
        PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
        Nat Genet. 2007; 39: 165-167
        • Tischkowitz M.
        • Xia B.
        • Sabbaghian N.
        • et al.
        Analysis of PALB2/FANCN-associated breast cancer families.
        Proc Natl Acad Sci U S A. 2007; 104: 6788-6793
        • Evans M.K.
        • Longo D.L.
        PALB2 mutations and breast-cancer risk.
        N Engl J Med. 2014; 371: 566-568
        • Jones S.
        • Hruban R.H.
        • Kamiyama M.
        • et al.
        Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
        Science. 2009; 324: 217
        • Antoniou A.C.
        • Casadei S.
        • Heikkinen T.
        • et al.
        Breast-cancer risk in families with mutations in PALB2.
        N Engl J Med. 2014; 371: 497-506
        • Morgan N.V.
        • Essop F.
        • Demuth I.
        • et al.
        A common Fanconi anemia mutation in black populations of sub-Saharan Africa.
        Blood. 2005; 105: 3542-3544
        • Faivre L.
        • Guardiola P.
        • Lewis C.
        • et al.
        Association of complementation group and mutation type with clinical outcome in Fanconi anemia. European Fanconi Anemia Research Group.
        Blood. 2000; 96: 4064-4070
        • El-Mouzan M.I.
        • Al-Salloum A.A.
        • Al-Herbish A.S.
        • et al.
        Regional variations in the prevalence of consanguinity in Saudi Arabia.
        Saudi Med J. 2007; 28: 1881-1884
        • Shimamura A.
        • Montes de Oca R.
        • Svenson J.L.
        • et al.
        A novel diagnostic screen for defects in the Fanconi anemia pathway.
        Blood. 2002; 100: 4649-4654